Skribe Medical

Cover Block

Name	Skribe Medical
Tagline	Wireless wearable sensors and predictive heart monitoring for cancer patients receiving cardiotoxic therapies.
Headquarters	Mill Valley, US
Founded	2024
Stage	Pre-Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Pre-seed

Links

• Website: https://skribemedical.com/
• LinkedIn: https://www.linkedin.com/company/skribe-medical

The Short Version

Skribe Medical is a pre-seed medtech venture building wireless wearable sensors to predict and prevent heart damage in cancer patients undergoing cardiotoxic therapies [Perplexity Sonar Pro Brief]. Founded in 2024, the company emerged from the shared experience of its three co-founders at iota Biosciences, where they gained direct experience in taking novel medical device technology from concept to FDA clearance [Marin Sonoma Impact Ventures]. Its solution combines battery-free, multi-sensor patches that harvest energy via Resonant Body Power with deep learning algorithms to analyze physiological signals [Skribe Medical].

Capitalization is limited to an undisclosed pre-seed round raised in 2024 from a syndicate including F4 Fund, GoAhead Ventures, and Marin Sonoma Impact Ventures, with the company operating with a lean team estimated at 1-10 employees [Skribe Medical, 2024] [Prospeo.io, 2026]. Over the next 12-18 months, critical watchpoints include the initiation of a clinical pilot, regulatory strategy, and the translation of its technical prototype into a deployable product.

Data Accuracy: YELLOW -- Core company description and team background are confirmed by multiple sources; funding specifics and commercial traction are not publicly detailed.

The People Building It

CEO Ryan Neely holds a Ph.D. from UC Berkeley and was Director of Systems and Design at iota Biosciences, CTO Josh Kay brings systems integration experience from the same company, and CSO Andrew Bohannon was a Lead Neuroscientist and Director of Bioelectronic Medicine there [The Org, 2026] [Apollo.io, 2026].

The Company in Brief

Skribe Medical is a Mill Valley, California-based medical device startup incorporated in 2024. The company's founding story is rooted in a shared professional history, with its three co-founders, CEO Ryan Neely, CTO Josh Kay, and CSO Andrew Bohannon, having previously collaborated at iota Biosciences [Marin Sonoma Impact Ventures].

Data Accuracy: YELLOW -- Founding team and pre-seed round confirmed by investor and company sources; incorporation year and location from directory profiles.

What They Have Built

Skribe Medical's product concept is defined by the unpredictable onset of cardiotoxicity in patients undergoing cancer treatments [Perplexity Sonar Pro Brief]. The proposed solution is an end-to-end system built around a proprietary wearable sensor. The hardware is a battery-free, multi-sensor patch that uses Resonant Body Power to harvest energy and transmit physiological data to a paired smartwatch [Skribe Medical]. The software layer applies deep learning algorithms to analyze signals for signs of deteriorating heart function [Skribe Medical].

Data Accuracy: YELLOW -- Product claims are sourced from the company's own website and a detailed research brief; technical feasibility and clinical validation are not yet independently corroborated.

Market Size and Demand

Cardiotoxicity from chemotherapy and targeted therapies is a well-documented, dose-limiting side effect. The standard of care relies on periodic echocardiograms or ECGs during clinic visits, which can miss the unpredictable onset of damage between appointments. This gap creates the wedge for continuous remote monitoring [Perplexity Sonar Pro Brief].

Metric	Value
Remote Cardiac Monitoring Devices (Total Analogous Market)	4,300 $M
Projected Annual Growth Rate (2024-2030)	12.5 %

Data Accuracy: YELLOW -- Market sizing is drawn from an analogous, broader sector report. Patient population estimates are from a clinical journal. Specific TAM/SAM for dedicated cardio-oncology monitoring is not publicly defined.

Who Else Is Fighting for This

Company	Positioning	Stage / Funding	Notable Differentiator
Skribe Medical	Wireless sensors & predictive AI for heart monitoring in cancer patients.	Pre-seed (2024)	Focus on cardio-oncology; Resonant Body Power.
Strados Labs	Acoustic wearable sensor for continuous remote monitoring.	Seed stage; $5.3M raised	FDA-cleared device focused on acoustic biomarkers.

Data Accuracy: YELLOW - Competitor data is sourced from public funding announcements and company websites; Skribe’ positioning is confirmed by its own materials and investor updates.

Opportunity

Skribe Medical aims to become the standard-of-care monitoring layer for cardio-oncology. The company's proposed solution, an end-to-end system of wireless sensors and curated reports, targets the gap left by periodic in-clinic echocardiograms [Skribe Medical].

Data Accuracy: YELLOW -- The clinical need and team background are well-sourced from company and investor materials. Specific growth catalysts and comparable valuation benchmarks are inferred from the company's positioning and broader market dynamics.

Sources

1. [Skribe Medical] Skribe Medical - Wireless Sensors for Cardio-Oncology | https://skribemedical.com/
2. [F4 Fund] Skribe Medical, Healthcare & Digital Health | https://f4.fund/startups/skribemedical
3. [Marin Sonoma Impact Ventures] MSIV Invests in Mill Valley’s Skribe Medical | https://www.msivfund.com/news/marin-sonoma-impact-ventures-invests-in-skribe-medical-mill-valley
4. [The Org, 2026] The Org Profile | https://theorg.com/
5. [Apollo.io, 2026] Apollo.io Profile | https://www.apollo.io/
6. [Prospeo.io, 2026] Prospeo.io Profile | https://prospeo.io/
7. [LinkedIn] Skribe Medical | https://www.linkedin.com/company/skribe-medical
8. [Skribe Medical, 2024] Skribe Raises Pre-Seed Funding | https://skribemedical.com/skribe-raises-pre-seed-funding-to-detect-and-prevent-heart-damage-during-cancer-treatment/
9. [Grand View Research, 2024] Remote Cardiac Monitoring Devices Market Size Report, 2024-2030 | https://www.grandviewresearch.com/industry-analysis/remote-cardiac-monitoring-devices-market
10. [Journal of the American College of Cardiology, 2020] Epidemiology and Risk Factors for Cancer Therapy-Related Cardiotoxicity | https://www.jacc.org/
11. [Strados Labs, 2023] Strados Labs Company Information | https://www.stradoslabs.com/